The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease
Open accessAbstract
Gaucher disease is a lysosomal storage disorder caused by deficient lysosomal β-glucosidase (β-Glu) activity. A marked decrease in enzyme activity results in progressive accumulation of the substrate (glucosylceramide) in macrophages, leading to hepatosplenomegaly, anemia, skeletal lesions, and sometimes CNS involvement. Enzyme replacement therapy for Gaucher disease is costly and relatively ineffective for CNS involvement. Chemical chaperones have been shown to stabilize various proteins against misfolding, increasing proper trafficking from the endoplasmic reticulum. We report herein that the addition of subinhibitory concentrations (10 μM) of N -( n -nonyl)deoxynojirimycin (NN-DNJ) to a fibroblast culture medium for 9 days leads to a 2-fold increase in the activity of N370S β-Glu, the most common mutation causing Gaucher disease. Moreover, the increased activity persists for at least 6 days after the withdrawal of the putative chaperone. The NN-DNJ chaperone also increases WT β-Glu activity, but not that of L444P, a less prevalent Gaucher disease variant. Incubation of isolated soluble WT enzyme with NN-DNJ reveals that β-Glu is stabilized against heat denaturation in a dose-dependent fashion. We propose that NN-DNJ chaperones β-Glu folding at neutral pH, thus allowing the stabilized enzyme to transit from the endoplasmic reticulum to the Golgi, enabling proper trafficking to the lysosome. Clinical data suggest that a modest increase in β-Glu activity may be sufficient to achieve a therapeutic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebícek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02161-9 · Cited by 744
Fan, J.-Q., Ishii, S., Asano, N., & Suzuki, Y. (1999) · Nature Medicine · doi:10.1038/4801 · Cited by 614
Morello, J.-P., Salahpour, A., Laperrière, A., Bernier, V., Arthus, M.-F., Lonergan, M., Petäjä-Repo, U., Angers, S., Morin, D., Bichet, D. G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8688 · Cited by 565
Sears, P., & Wong, C.-H. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990816)38:16<2300::aid-anie2300>3.0.co;2-6 · Cited by 516
Self-citationPetaja-Repo, U. E. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1628 · Cited by 262
Asano, N., Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin, O. R., & Fan, J. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01457.x · Cited by 242
Pharmacological chaperones: a new twist on receptor folding
Morello, J.-P., Bouvier, M., Petäjä-Repo, U. E., & Bichet, D. G. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01575-3 · Cited by 241
Gaucher disease: gene frequencies in the Ashkenazi Jewish population.
Beutler, E., Nguyen, N. J., Henneberger, M., Smolec, J. M., McPherson, R. A., West, C., & Gelbart, T. (1993) · PubMed · Cited by 230
Self-citationGeneration of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase
Overkleeft, H. S., Renkema, G. H., Neele, J., Vianello, P., Hung, I. O., Strijland, A., van der Burg, A. M., Koomen, G.-J., Pandit, U. K., & Aerts, J. M. F. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26522 · Cited by 186
The molecular basis of lysosomal storage diseases and their treatment
Winchester, B., Vellodi, A., & Young, E. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280150 · Cited by 178
Butters, T. D., van den Broek, L. A. G. M., Fleet, G. W. J., Krülle, T. M., Wormald, M. R., Dwek, R. A., & Platt, F. M. (2000) · Tetrahedron Asymmetry · doi:10.1016/s0957-4166(99)00468-1 · Cited by 147
Mutations in Jewish patients with Gaucher disease
Beutler, E., Gelbart, T., Kühl, W., Zimran, A., & West, C. (1992) · Blood · doi:10.1182/blood.v79.7.1662.1662 · Cited by 144
Self-citationAnalysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression.
Grace, M., Newman, K., Scheinker, V., Berg-Fussman, A., & Grabowski, G. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42166-1 · Cited by 138
Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease.
Raghavan, S. S., Topol, J., & Kolodny, E. H. (1980) · Europe PMC (PubMed Central) · Cited by 125
Gaucher disease: perspectives on a prototype lysosomal disease
Zhao, H., & Grabowski, G. A. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8458-y · Cited by 121
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy
Platt, F. M., Jeyakumar, M., Andersson-Hall, U. K., Priestman, D. A., Dwek, R. A., Butters, T. D., Cox, T. M., Lachmann, R., Hollak, C. E. M., Aerts, J. M. F. G., et al. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1010335505357 · Cited by 119
Berg-Fussman, A., Grace, M., Ioannou, Y. A., et al. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82412-7 · Cited by 109
New Prospects for the Treatment of Lysosomal Storage Diseases
Schiffmann, R., & Brady, R. O. (2002) · Drugs · doi:10.2165/00003495-200262050-00002 · Cited by 98
Gaucher disease. Enzymology, genetics, and treatment.
Grabowski, G. A. (1993) · PubMed · Cited by 90
Beta-glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher's disease.
Beutler, E., Kühl, W., Trinidad, F., Teplitz, R. L., & Nadler, H. L. (1971) · Europe PMC (PubMed Central) · Cited by 88
Self-citationGaucher disease mutations in non‐Jewish patients
Beutler, E., & Gelbart, T. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb03185.x · Cited by 68
Self-citationQuantitative Analysis of the Targeting of Mannose‐Terminal Glucocerebrosidase
Bijsterbosch, M. K., Donker‐Koopman, W. E., van de Bilt, H., van Weely, S., van Berkel, T. J. C., & Aerts, J. M. F. G. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00344.x · Cited by 61
Durand, P., Fabrega, S., Henrissat, B., Mornon, J. P., & Lehn, P. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.6.967 · Cited by 20
Cited by
Protein misfolding in the endoplasmic reticulum as a conduit to human disease
Wang, M., & Kaufman, R. J. (2016) · Nature · doi:10.1038/nature17041 · Cited by 1,630
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Self-citationTherapeutic approaches to protein-misfolding diseases
Cohen, F. E., & Kelly, J. W. (2003) · Nature · doi:10.1038/nature02265 · Cited by 800
Self-citationThe cell biology of lysosomal storage disorders
Futerman, A. H., & van Meer, G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1423 · Cited by 796
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Metadata
- Authors
- Sawkar, A. R., Cheng, W.-C., Beutler, E., Wong, C.-H., Balch, W. E., & Kelly, J. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-11-14
- Volume
- 99
- Issue
- 24
- Pages
- 15428-15433
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1758125525
- Cited by
- 503
- References
- 23
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.